Hemostemix Inc. (CVE:HEM – Get Free Report) shot up 48.3% during mid-day trading on Thursday . The stock traded as high as C$0.24 and last traded at C$0.22. 599,100 shares changed hands during mid-day trading, an increase of 40% from the average session volume of 426,900 shares. The stock had previously closed at C$0.15.
Hemostemix Price Performance
The firm has a market capitalization of C$20.91 million, a price-to-earnings ratio of -12.00 and a beta of 0.20. The firm has a 50 day moving average price of C$0.09 and a 200-day moving average price of C$0.07.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Stories
- Five stocks we like better than Hemostemix
- How to Use the MarketBeat Excel Dividend Calculator
- Driving Forward: Lucid’s Growing Sales and Gravity SUV’s Impact
- Comparing and Trading High PE Ratio Stocks
- Why Amazon’s Next Earnings Could Trigger a Stock Breakout
- Roth IRA Calculator: Calculate Your Potential Returns
- With This Kind of Data, The Fed Isn’t Cutting Rates This Year
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
